Sammenlagte data fra fire 1- års kliniske studier med adipøse type 2- diabetespatienter, der var utilstrækkeligt kontrolleret med antidiabetika, viste, at procentdelen af respondenter (≥ 10% tab af legemsvægt) var 11, 3% blandt dem, der fik orlistat sammenlignet med 4, 5% blandt dem, der fik placebo.
In obese type 2 diabetic patients insufficiently controlled by antidiabetic agents, data from four one- year clinical trials showed that the percentage of responders (≥ 10% of body weight loss) was 11.3% with orlistat as compared to 4.5% with placebo.